FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL											
OMB Number: 3235-028											
Estimated average burden											
hours per response:	0.5										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>TANNENBAUM RENEE P</u>					2. Issuer Name and Ticker or Trading Symbol Cardiff Oncology, Inc. [ CRDF ]									elationship of the control of the co	able)	g Pers	son(s) to Iss 10% Ov		
(Last) 11055 FI	`	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/09/2022									Officer below)	(give title		Other (s below)	specify
C/O CARDIFF ONCOLOGY, INC.				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)	EGO C	A	92121											Line	Form f	led by More		orting Perso orting Repo	
(City)	(S	itate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/D:					Execution Date		Date,	, Transaction I		Disposed	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amour Securitie Beneficia Owned F Reported	es For ally (D) Following (I) (		ownership m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(/	A) or D)	Price	Transact	Transaction(s) (Instr. 3 and 4)			(111511.4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\)		ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			of Sec Under Deriva	curities	ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	ode	v	(A)	(D)	Date Exercisal		expiration Pate	Title	100	Amount or Number of Shares					
Stock Options	\$2.5	03/09/2022			A		26,800		03/09/20	23 0	3/09/2032	Comm		26,800	\$0	70,801	]	D	

**Explanation of Responses:** 

Remarks:

/s/ Renee P Tannenbaum

03/10/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).